PPD Receives Award Recognizing Employee Talent Development
WILMINGTON, N.C. (Sept. 1, 2021) –
PPD is a recipient of the 2021 ATD BEST Awards, which recognize enterprise-wide success as a result of employee talent development. PPD is committed to attracting, developing and retaining top talent in the industry, and this year, PPD ranked second out of 71 companies in the
“PPD goes to great lengths to invest in and develop our colleagues through our robust training programs, and this award reflects our successful efforts in providing effective professional development for our global workforce,” said
Employee learning and development at PPD includes leadership and high-potential development, key talent programs, technical skills, job-specific and soft skills training, all of which are integrated and aligned with business goals and objectives.
The ATD BEST Awards celebrate and honor those companies that use talent development as a strategic business tool to deliver results. Judges for the 2021 ATD BEST Awards received and reviewed hundreds of entries this year. As an award recipient, PPD successfully demonstrated that it has excelled in various aspects of talent development, including creating solutions to business issues, providing learning opportunities for employees at all levels within the company and measuring the effectiveness of its learning programs.
ATD’s members and customers come from more than 120 counties, and they are professionals who help others achieve their full potential by improving their knowledge, skills and abilities in the workplace.
PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our customers and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With more than 28,000 professionals worldwide, PPD has conducted clinical trials in more than 100 countries to help customers deliver life-changing therapies to improve health. We apply innovative technologies, therapeutic expertise and a firm commitment to quality to bend the cost and time curve of drug development and optimize value. For more information, visit www.ppd.com.
This news release contains forward-looking statements. These statements often include words such as “expect,” “believe,” “project,” “forecast,” “estimate,” “target” and other similar expressions. Although we believe these forward-looking statements are based on reasonable assumptions at the time they are made, you should be aware that many factors could affect our actual financial results, and therefore actual results might differ materially from those expressed in the forward-looking statements. Factors that might materially affect such forward-looking statements include, but are not limited to, the fragmented and highly competitive nature of the drug development services industry; changes in trends in the biopharmaceutical industry; our ability to keep pace with rapid technological changes that could make our services less competitive or obsolete; political, economic and/or regulatory influences and changes; the risks related to the proposed merger of PPD by Thermo Fisher Scientific Inc.; and other factors disclosed under the “Risk Factors” section in our periodic reports filed with the
+1 919 456 4425
+1 910 558 4186